195 related articles for article (PubMed ID: 23065693)
41. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type.
Bortolin MT; Pratesi C; Dolcetti R; Bidoli E; Vaccher E; Zanussi S; Tedeschi R; De Paoli P
Cancer Lett; 2006 Feb; 233(2):247-54. PubMed ID: 15907367
[TBL] [Abstract][Full Text] [Related]
42. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
43. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes.
Chang KP; Hao SP; Chang JH; Wu CC; Tsang NM; Lee YS; Hsu CL; Ueng SH; Liu SC; Liu YL; Wei PC; Liang Y; Chang YS; Yu JS
Clin Cancer Res; 2008 Nov; 14(21):6979-87. PubMed ID: 18980993
[TBL] [Abstract][Full Text] [Related]
44. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients.
Chan KC; Leung SF; Yeung SW; Chan AT; Lo YM
Clin Cancer Res; 2008 Aug; 14(15):4809-13. PubMed ID: 18676752
[TBL] [Abstract][Full Text] [Related]
45. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.
Lo YM; Chan LY; Lo KW; Leung SF; Zhang J; Chan AT; Lee JC; Hjelm NM; Johnson PJ; Huang DP
Cancer Res; 1999 Mar; 59(6):1188-91. PubMed ID: 10096545
[TBL] [Abstract][Full Text] [Related]
46. Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma.
Huang CL; Sun ZQ; Guo R; Liu X; Mao YP; Peng H; Tian L; Lin AH; Li L; Shao JY; Sun Y; Ma J; Tang LL
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):355-361. PubMed ID: 30682489
[TBL] [Abstract][Full Text] [Related]
47. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma.
Prayongrat A; Chakkabat C; Kannarunimit D; Hansasuta P; Lertbutsayanukul C
J Radiat Res; 2017 Jul; 58(4):509-516. PubMed ID: 28204596
[TBL] [Abstract][Full Text] [Related]
48. Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis.
Liu TB; Zheng ZH; Pan J; Pan LL; Chen LH
Clin Invest Med; 2017 Feb; 40(1):E1-E12. PubMed ID: 28218577
[TBL] [Abstract][Full Text] [Related]
49. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
Lo YM; Chan LY; Chan AT; Leung SF; Lo KW; Zhang J; Lee JC; Hjelm NM; Johnson PJ; Huang DP
Cancer Res; 1999 Nov; 59(21):5452-5. PubMed ID: 10554016
[TBL] [Abstract][Full Text] [Related]
50. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
[TBL] [Abstract][Full Text] [Related]
51. Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.
Westmoreland KD; Montgomery ND; Stanley CC; El-Mallawany NK; Wasswa P; van der Gronde T; Mtete I; Butia M; Itimu S; Chasela M; Mtunda M; Kampani C; Liomba NG; Tomoka T; Dhungel BM; Sanders MK; Krysiak R; Kazembe P; Dittmer DP; Fedoriw Y; Gopal S
Int J Cancer; 2017 Jun; 140(11):2509-2516. PubMed ID: 28268254
[TBL] [Abstract][Full Text] [Related]
52. The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma.
Ma BB; Mo FK; Chan AT; Hui EP; Leung SF; Lo YM; Yau YY; King AD
Oral Oncol; 2008 Nov; 44(11):1067-72. PubMed ID: 18396444
[TBL] [Abstract][Full Text] [Related]
53. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer.
Shotelersuk K; Khorprasert C; Sakdikul S; Pornthanakasem W; Voravud N; Mutirangura A
Clin Cancer Res; 2000 Mar; 6(3):1046-51. PubMed ID: 10741733
[TBL] [Abstract][Full Text] [Related]
54. [Correlation between the kinetics of plasma EBV DNA levels and clinical response during treatment in patients with nasopharyngeal carcinoma].
Peng PJ; Zhao C; Liao H; Wang FQ; Zhang L
Ai Zheng; 2002 Aug; 21(8):817-22. PubMed ID: 12478884
[TBL] [Abstract][Full Text] [Related]
55. The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma.
Chang KP; Hao SP; Lin SY; Ueng SH; Pai PC; Tseng CK; Hsueh C; Hsieh MS; Yu JS; Tsang NM
Laryngoscope; 2006 Apr; 116(4):541-6. PubMed ID: 16585856
[TBL] [Abstract][Full Text] [Related]
56. Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.
Stoker SD; Wildeman MA; Novalic Z; Fles R; van der Noort V; de Bree R; Braunius WW; van den Broek GB; Kreike B; Kross KW; Juwana H; Ramayanti O; Verkuijlen SA; de Boer JP; Greijer AE; Middeldorp JM; Tan IB
Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1557-67. PubMed ID: 25929413
[TBL] [Abstract][Full Text] [Related]
57. Effects of Epstein-Barr virus viral load and different treatment modality for stage III nasopharyngeal carcinoma.
Twu CW; Wang WY; Tsou HH; Liu YC; Jiang RS; Liang KL; Lin PJ; Lin TY; Chen HH; Lin JC
Head Neck; 2020 Aug; 42(8):1765-1774. PubMed ID: 32011052
[TBL] [Abstract][Full Text] [Related]
58. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study.
Tang LQ; Li CF; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Chen WH; Liu H; Guo SS; Liu LT; Li J; Zhang JP; Guo L; Zhao C; Cao KJ; Qian CN; Zeng YX; Guo X; Mai HQ; Zeng MS
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):325-36. PubMed ID: 25482300
[TBL] [Abstract][Full Text] [Related]
59. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.
To EW; Chan KC; Leung SF; Chan LY; To KF; Chan AT; Johnson PJ; Lo YM
Clin Cancer Res; 2003 Aug; 9(9):3254-9. PubMed ID: 12960110
[TBL] [Abstract][Full Text] [Related]
60. Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma.
Chen M; Yin L; Wu J; Gu JJ; Jiang XS; Wang DJ; Zong D; Guo C; Zhu HF; Wu JF; He X; Guo WJ
Biomed Res Int; 2015; 2015():617949. PubMed ID: 25802858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
